Evidence map›Paper›PMID 32750261›Full record

ArticleHuman vaccines & immunotherapeutics2021

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants.

Marissa B Wilck, Z Jin Xu, Jon E Stek, Andrew W Lee

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05266664 (Preterm Immune System Development and Response to Immunization), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05266664 unknown statusnot on this mapstarted 2022, after this paper: background citation

Preterm Immune System Development and Response to Immunization

TypeobservationalSponsorMaastricht University Medical CenterRan2022 to 2026Enrolled145ConditionsImmune System Disorder, Preterm, Vaccination Failure
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Marissa B WilckMerck & Co., Inc ., Kenilworth, NJ, USA.ORCID 0000-0002-6890-1118
Z Jin XuMerck & Co., Inc ., Kenilworth, NJ, USA.
Jon E StekMerck & Co., Inc ., Kenilworth, NJ, USA.ORCID 0000-0001-7521-874X
Andrew W LeeMerck & Co., Inc ., Kenilworth, NJ, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Haemophilus influenzae type bHaemophilus VaccinesAntibodies, BacterialCanadaChildDiphtheria-Tetanus-Pertussis VaccineHepatitis B VaccinesHumansInfantInfant, Low Birth WeightInfant, NewbornInfant, PrematurePoliovirus Vaccine, InactivatedVaccines, CombinedAntibodies, BacterialDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesPoliovirus Vaccine, InactivatedVaccines, CombinedDTaP-IPV-Hib-HepB Vaccineimmunogenicityintegrated analysespremature infantsSafety

Identifiers

PMID32750261
PMCPMC7872088
OpenAlexW3047216808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.